(NewsDirect)
By Julian Richard,Benzinga
Successful Autologous Cell-BasedTherapies
Theglobal CAR-T cell therapy market is growing continuously due to novelclinical and commercial developments in this therapy. As a result, theGlobal CAR-T cell therapy market is expected to be worth USD 4.36billion by 2028 from 2.31 billion in 2023, growing with a healthy CAGRof 13.5% during the forecast period. Companies like Pfizer (NYSE: PFE)Johnson & Johnson (NYSE: JNJ, Bristol-Meyers Squibb (NYSE: BMY) aswell as Gilead Sciences (NASDAQ: GILD) all are focusing on thisinnovative CAR-T cell therapy.
Autologous cell based therapies are personalizedtherapies using your own cells to target a disease or disorder.Personalized therapies targeting cancer such CAR-T cell therapies havegenerated impressive clinical results with complete remission rates inB-acute lymphoblastic leukemia in over >80% of patients. One of thereasons this therapy has been successful is because it isautologous.
In 2017, the U.S. FDAapproved the first two CAR-T cell therapies: Novartis’ Kymriah® fortreatment of acute lymphoblastic leukemia (ALL) and Gilead subsidiaryKite Pharma’s Yescarta® for certain types of large B-celllymphomas, a type of non-Hodgkin lymphoma. These autologous therapiesare patient-specific where the therapeutic CAR-T cells are createdfrom a patient’s own cells.
The Value of AutologousStem-Cell Therapies
Autologous stem-cell therapy is a novel medical technology thatis revolutionizing the way the medical community approaches thetreatment of metabolic, autoimmune and degenerative diseases.Additionally, this technique has been used successfully to developskin grafts for wound care, treat burns and bedsores and speed uprecovery after surgery.
The method involves extracting stem cells from a patient’sbody and culturing them in laboratory conditions before reintroducingthem into the patient. Stem cells are a unique type of cell that candevelop into any other cell in the body. These “supercharged”cells can be used for tissue regeneration and repair, making stemcells a potent tool in modern personalized medicine. Stratifiedmedicine simply cannot compete with this customization,precision, and safety profile.
The main benefit of using autologous cells is thatthese cells come from your own body and therefore do not trigger any immunologicalrejection reactions . They also minimizethe risk of infection from non-patient sources. This allowsautologous cell therapy to be used safely over a longer term, ensuringthat the patient can access consistent and reliable treatment withoutrisk of rejection or complications due to incompatibility.
In 2021, the autologous cell therapy marketwas valued at $4.3billion and was projected to skyrocket to $29.1 billion by2031—marking a compounded annual growth rate (CAGR) of 21% from2022-2031. Although the market is still nascent, it is expected toeventually create a new healthcare sector with revenuesimilar to that of the pharmaceutical, biotechnological, andmedical devices industries.
An Autologous Stem Cell-BasedApproach to treat Disc Pain
BioRestorative Therapies Inc (NASDAQ:BRTX) focuses on innovative “home-grown” autologousstem-cell therapies to address unmet needs in patients with common yetserious diseases. It was founded by medical doctors, scientists andworld-renowned stem-cell researchers committed to developing novelstem-cell therapies.
The lead candidate in BioRestorative’s musculoskeletalstem-cell platform is BRTX-100, administered as a minimally-invasivesingle intradiscal injection. BRTX-100 is currently being evaluated inan FDA gold standard phase 2 double-blind, controlled, randomizedstudy in those with chronic lumbar disc disease (cLDD).
Chronic lumbar discdisease affects over 500million individuals globally and is currently only treatablewith opioids and surgery. Despite being the most commonlyprescribed drug for cLLD, no clinical data supports the use ofopioids in cLLD, which only serves to increase the opioidcrisis in the USA.
Surgery for cLLD carries many disadvantages andlimitations. The cost of surgery can be high. While surgicalintervention may reduce pain in some cases, it often fails to restoreprevious levels of function or mobility. Revision or reoperation ratesfor surgical intervention in the spine can be upwards of 20-30% of thecases performed. Furthermore, a more extended recovery period isassociated with an increased risk of mechanical instability of thespine and potentially increased failure rates compared to non-surgicaltreatments.
Itwould appear a bright future awaits BioRestorative Therapies and theautologous cell therapy market in general as patients increasinglylook at personalized alternatives to surgery and conventionalmedicine. BRTX-100 is an innovative and minimally-invasive technologyset to revolutionize lower back pain treatment.
Visit https://www.biorestorative.com for more information on the company and its product candidates.
This article was originally published onBenzinga here .
BioRestorativeTherapies was founded by scientists and researchers committed todeveloping stem cell therapies to address unmet needs in patients withhighly prevalent conditions.Our advances in stem cell biology anddelivery protocols harbor great promise in conditioning our bodies’own regenerative potential to treat major diseases more effectivelythan current interventions.Today, BioRestorative is activelydeveloping programs that aim to dramatically increase quality of carefor both (i) chronic back pain caused by disc degeneration, as well as(ii) metabolic disorders including obesity anddiabetes.
This post contains sponsored advertisingcontent. This content is for informational purposes only and is notintended to be investing advice.
ContactDetails
Investor Relations
CompanyWebsite
https://www.biorestorative.com/
Copyright (c) 2023 TheNewswire - All rights reserved.